People Category: Leadership Team

Mr. DiLeo joined Anokion in 2018 to lead its then corporate alliance with Celgene (later BMS) and advance preclinical programs toward IND. Shortly after joining, Mr. DiLeo was named program lead for ANK-700 in multiple sclerosis leading the program to delivery of key milestones in 2019 and following a successful IND submission in 2020. Mr. DiLeo brings over 20 years of product development and operations experience to Anokion leading technical programs and external relationships across a variety of products and therapeutic areas. Prior to joining Anokion, Mr. DiLeo spent over 11 years at Dyax Corp. in a variety of roles, ultimately being named program manager for the landelumab antibody program in HAE, where he participated in the program’s eventual sale to Shire plc and into Phase 3. Prior to joining Anokion, Mr. DiLeo led commercial manufacturing efforts and launch-related supply activities at TESARO. Mr. DiLeo spent his early career at Biogen and Millipore Corporation.

Mr. DiLeo holds B.S. and M.S. degrees in Chemical Engineering as well as an M.B.A. all from Rensselaer Polytechnic Institute.

Ms. Luosey joined Anokion in August 2023 as Senior Vice President, Product and Development Operations. Nicole brings over 20 years of experience in product strategy and development operations, corporate planning, and program execution across multiple therapeutic areas and modalities. She has led a variety of product development teams and managed program and alliance management functions across various stages of drug development. Most recently, Ms. Luosey served as vice president, portfolio strategy and program management at Replimune where she was responsible for leading the product development teams across the portfolio, along with developing the program management function and R&D governance process. Prior, Ms. Luosey held similar roles at and led diligence and integration efforts for a number of sell-side M&A transactions, including the acquisitions of Cadent Therapeutics by Novartis and Syntimmune by Alexion. Earlier in her career, Ms Luosey held a variety of program management roles at Dimension Therapeutics, Merrimack Pharmaceuticals, EMD Serono, and Dyax.

Ms. Luosey is a certified Project Management Professional (PMP) and received her M.S. in Project Management from Boston University and B.F.A. from the University of Hartford.

Ms. Haller joined Anokion in 2022 as Senior Vice President, Clinical Operations. Stephanie brings extensive experience in the strategic planning and execution of phase 1-4 clinical trials. She has helped direct clinical research activities across numerous early and late-stage clinical trials in the last decade. Most recently Ms. Haller served as Vice President, Clinical Operations at Alexion Pharmaceuticals following that company’s acquisition of Syntimmune. While at Alexion/Syntimmune, Ms. Haller served as clinical operations therapeutic area lead for nephrology and FcRn franchise lead. Prior to this, Ms. Haller was Vice President, Clinical Operations at Dimension Therapeutics. While at Dimension she was instrumental in the successful clinical evaluation of multiple gene therapy assets, contributing to the acquisition of the company by Ultragenyx. Prior to Dimension, Ms. Haller served as Director, Clinical Programs at Shire plc, where she oversaw global clinical development plans for early-phase, rare disease assets. Earlier in her career, Stephanie held positions of increasing responsibility at Halloran Consulting Group, Genzyme Corporation, Muro Pharmaceuticals, and ICON Clinical Research. She earned a B.A. in Psychology from Denison University and an M.S. in Experimental Psychology from Villanova University.

Dr. Grebe joined Anokion in 2019 bringing over 20 years of experience in immunological, clinical and translational research. Most recently she served as Senior Vice President, Immunology and Translational Medicine at Anokion where she functioned as clinical development lead for the celiac and multiple sclerosis ph1 trials. Throughout her career she has led and supported translational teams from discovery through phase 3b/IV across of range of small molecule and biologic programs for gastroenterology, rheumatology and dermatology indications. Prior to joining Anokion, Dr. Grebe spent more than a decade in positions of increasing responsibility at Abbvie where she led the clinical translational strategy for multiple programs in the Immunology pipeline, including Skyrizi. Dr. Grebe earned a B.S. in Microbiology and Cell Science from the University of Florida, a Ph.D. in Microbiology and Immunology from the University of Colorado Health Science Center and completed a postdoctoral fellowship in the Laboratory of Viral Disease at the National Institutes of Health.

Mr. Booma joined Anokion in 2022 as Chief Strategy Officer. He has deep experience leading product planning and portfolio strategy across a range of platforms and clinical indications. He has played a key role in the advancement of 15 programs into the clinic and approval/marketing of 6 products. Prior to Anokion, Glenn spent nearly a decade providing consulting to life sciences companies and investors, focused on portfolio strategy, new product commercialization and business development. Prior to this, Mr. Booma served as Senior Director, Strategic Market Development at Springleaf Therapeutics where he led the company’s portfolio strategy and commercial insights functions supporting financings, IND filing, and a successful first-in-human clinical program. Previously, he served in portfolio strategy and marketing roles at Cyberkinetics Neurotechnology Systems, Transform Pharmaceuticals (acquired by Johnson & Johnson), Control Delivery Systems (acquired by Psivida/EyePoint Pharmaceuticals), and Genzyme. Earlier, he was a business strategy consultant focused on the pharmaceutical and medical device industries at Charles River Associates and was a medical service representative at Pfizer. Mr. Booma holds a B.A. in biology from the University of Vermont and an M.S. in evaluative clinical sciences from Dartmouth College.

Dr. Cooper joins Anokion from AbbVie, where he was most recently asset strategy leader with responsibility for the development of risankizumab, an anti-IL-23 antibody, across multiple indications. He has served in multiple senior roles and brings more than 20 years of diverse clinical development experience, including biological drug development in immunology. Prior to AbbVie, Dr. Cooper was vice president, global project head, immunology and inflammation at Sanofi, where he led the development of KEVZARA^® sarilumab, an IL-6R antibody approved to treat rheumatoid arthritis (RA). He played a key role in its worldwide submission in RA and was a lead in the development of the product’s global launch. Previously, Dr. Cooper was global program medical director at Novartis, executive director, clinical research for Human Genome Sciences (now part of GlaxoSmithKline), and clinical science leader at Roche. In these roles, he was instrumental in the development and approvals for Benlysta^® belimumab, Cosentyx^® secukinumab and Rituxan^® rituximab. He earned his Bachelor of Medicine, Bachelor of Surgery at University of Newcastle upon Tyne Medical School, before undertaking his higher medical training in Oxford.

Hilda Buehler joined Anokion in 2015, leading the early establishment of the company’s finance and accounting functions. She brings more than 15 years of finance and accounting experience to Anokion, currently serving as senior director of finance and corporate controller. Hilda is a Certified Public Accountant (CPA) and has lived in Switzerland for 28 years, maintaining dual citizenship in the US and Switzerland. Prior to Anokion, Ms. Buehler was finance director for a global information technology (IT) start-up with offices in the US, Switzerland and Belgium. Earlier in her career, Hilda managed international audits with KPMG in Los Angeles, CA, prior to transferring to its Geneva office. Hilda earned dual BAs in Business Administration and Accounting at Loyola Marymount University.

Dr. Geraghty joined Anokion in 2018 as Chief Business Officer and was most recently Chief Operating Officer of the company. Dr. Geraghty brings more than 20 years of extensive experience in the life sciences industry across corporate and portfolio strategy, commercial, and finance. Prior to Anokion, Dr. Geraghty was senior vice president of corporate strategy at Dimension Therapeutics, where she had a leading role in the company’s private and initial public offering financing execution, was responsible for driving gene therapy portfolio growth, and helped lead the acquisition of the company by Ultragenyx Pharmaceutical Inc. Previous to Dimension, Dr. Geraghty was a founder and vice president, project and portfolio development at Cydan Development, an orphan drug accelerator that raised $26 million to identify and de-risk assets with therapeutic and commercial potential. Earlier in her biotech career, Dr. Geraghty served as head of portfolio advancement at Aileron Therapeutics and as director of new product marketing at Infinity Pharmaceuticals. Dr. Geraghty was a founder of Back Bay Strategies and held multiple positions at Kendall Strategies, Feinstein Kean Healthcare, and Genzyme Corp.

Dr. Geraghty also serves on the Board of Directors of ReAlta Life Sciences, Inc., where she chairs the audit committee, and the Medical University of South Carolina (MUSC) Foundation for Research Development (FRD), the university’s technology transfer office since 1998. She earned a B.S. in Biology at Union College, an M.B.A. from the Carroll School at Boston College, and a Ph.D in Molecular Biology at the University of Vermont.